Live from the registry
Clinical trials
Live from the ClinicalTrials.gov registry. Registration is not endorsement: a registered trial may be small, early, or studying a single age-associated condition rather than ageing itself. Always read the registry entry before drawing conclusions.
Sirolimus Use in Angioplasty for Vascular Access Extension
completedLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · PHASE2 · 17 participants
Primary outcome measured: Comparison of the sirolimus group to the control group from time of assisted primary and secondary patency rates to access abandonment
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
terminatedM.D. Anderson Cancer Center · PHASE2 · 8 participants
Primary outcome measured: Objective Response Rate (ORR)
Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF
unknownInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · PHASE4 · 5 participants
Primary outcome measured: Change in calcineurin & mTOR inhibitors' blood concentrations after switch to B/F/TAF
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
completedM.D. Anderson Cancer Center · PHASE2 · 17 participants
Primary outcome measured: RCB Status
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
recruitingFudan University · PHASE2 · 265 participants
Primary outcome measured: Progression Free Survival (PFS)
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
completedNational Cancer Institute (NCI) · PHASE1, PHASE2 · 14 participants
Primary outcome measured: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II)
An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations
recruitingXuanwu Hospital, Beijing · PHASE2 · 10 participants
Primary outcome measured: Objective Response Rate (ORR) assessed by MRI
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
completedNational Cancer Institute (NCI) · PHASE2 · 53 participants
Primary outcome measured: Tumor Response
Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors
completedGustave Roussy, Cancer Campus, Grand Paris · PHASE1 · 45 participants
Primary outcome measured: Safety
Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
completedTampa General Hospital · PHASE4 · 26 participants
Primary outcome measured: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
recruitingUniversity of California, San Francisco · PHASE1 · 50 participants
Primary outcome measured: Maximum tolerated dose (MTD) of trametinib in combination with everolimus for both continuous and intermittent dosing schedules
Registration Trial of the Drug-coated Balloon for the Symptomatic Cerebral Atherosclerotic Stenosis
unknownMicroPort NeuroTech Co., Ltd. · NA · 212 participants
Primary outcome measured: Target lesion restenosis rate at 6 month postoperative
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
unknownUniversity of Liege · PHASE2 · 200 participants
Primary outcome measured: Progression-free survival
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
unknownChao Huang · PHASE1 · 15 participants
Primary outcome measured: Incidence of treatment-emergent adverse events.
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
withdrawnSt. Joseph's Healthcare Hamilton · PHASE2, PHASE3
Primary outcome measured: Malignancy-free survival
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
completedPediatric Brain Tumor Consortium · PHASE1 · 22 participants
Primary outcome measured: Maximum Tolerated Dose of Ribociclib and Everolimus
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
completedSusan Chang · PHASE2 · 58 participants
Primary outcome measured: Progression-free Survival at 6 Months.
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
active not recruitingMedSIR · PHASE2 · 14 participants
Primary outcome measured: To assess the efficacy of MEN1611 in combination with eribulin as determined by the clinical benefit rate (CBR).
Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)
unknownShanghai Children's Medical Center · PHASE4 · 36 participants
Primary outcome measured: Change of tumor size
Sirolimus for Cowden Syndrome With Colon Polyposis
completedOhio State University · PHASE2 · 5 participants
Primary outcome measured: Change in colon polyp burden by number
Source: ClinicalTrials.gov API v2, retrieved live and cached for one hour. Longevity Record is not affiliated with ClinicalTrials.gov or the US National Library of Medicine. Trial participation is a medical decision — see our disclaimer.